Articles Tagged With: Pharmacology
-
COVID-19: Beware Remdesivir Resistance
Researchers reported two immunosuppressed renal transplant recipients with persistent SARS-CoV-2 infection in association with the new emergence of mutations in RNA-dependent RNA polymerase after remdesivir treatment.
-
Fecal Microbiota, live-jslm (Rebyota)
Rebyota can be prescribed to prevent recurring Clostridioides difficile infection for patients age 18 years and older who are following antibiotic treatment for recurring episodes.
-
Long-Term Statin Use Associated with Lower Stroke Risk
A cohort of Danish patients who were taking the cholesterol control medication were less likely to experience an intracerebral hemorrhage.
-
Apixaban for Venous Thromboembolism in Patients with End-Stage Kidney Disease
There is a lower risk of bleeding for those taking apixaban during venous thromboembolism treatment compared to warfarin in patients with end-stage kidney disease.
-
Teplizumab-mzwv Injection (Tzield)
Teplizumab can be prescribed to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients age 8 years and older with stage 2 type 1 diabetes.
-
Is Long-Term Antidepressant Use Hurting Patients?
Long-term antidepressant use could lead to elevated risks of coronary heart disease, along with higher cardiovascular disease mortality and all-cause mortality rates.
-
The Right Dose at the Right Time: Improving Hypertension Outcomes
An online study of evening vs. morning administration of patients’ usual antihypertensive medications, with a median five-year follow-up, revealed there is no difference in major cardiovascular outcomes between the two periods.
-
Ruxolitinib Cream (Opzelura)
Ruxolitinib cream can be prescribed to treat nonsegmental (bilateral) vitiligo in adult and pediatric patients age 12 years and older.
-
Triglyceride-Lowering Therapy and Cardiovascular Events
Researchers studied pemafibrate vs. placebo in patients with type 2 diabetes, mild-to-moderate triglyceride elevations, and low levels of HDL and well-controlled LDL cholesterol. Despite a 31% reduction in triglyceride levels, there was no improvement in the risk of cardiovascular outcomes over a median follow-up of 3.4 years.
-
New Therapy for Resistant Hypertension
Aprocitentan demonstrated efficacy for additional therapy beyond standard multidrug treatment in resistant hypertension.